EMA — authorised 22 March 2002
- Status: approved
🇪🇺 Xapit in European Union
EMA authorised Xapit on 22 March 2002
Marketing authorisations
EMA — authorised 22 March 2002
- Application: EMEA/H/C/000380
- Marketing authorisation holder: Pharmacia Europe EEIG
- Local brand name: Xapit
- Indication: For the short-term treatment of postoperative pain.
- Status: withdrawn
EMA — authorised 22 March 2002
- Application: EMEA/H/C/000382
- Marketing authorisation holder: Pharmacia Europe EEIG
- Local brand name: Rayzon
- Indication: For the short-term treatment of postoperative pain.The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risks (see sections 4.3, 4.4).
- Status: withdrawn
Xapit in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Pain approved in European Union
Frequently asked questions
Is Xapit approved in European Union?
Yes. EMA authorised it on 22 March 2002; EMA authorised it on 22 March 2002; EMA authorised it on 22 March 2002.
Who is the marketing authorisation holder for Xapit in European Union?
Marketing authorisation holder not available in our data.